BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.